We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 05, 2020

Ramucirumab and Durvalumab for Previously Treated, Advanced NSCLC, Gastric/GEJ Adenocarcinoma, or HCC

European Journal of Cancer


Additional Info

European Journal of Cancer
Ramucirumab and Durvalumab for Previously Treated, Advanced Non-Small-Cell Lung Cancer, Gastric/Gastro-Oesophageal Junction Adenocarcinoma, or Hepatocellular Carcinoma: An Open-Label, Phase Ia/b Study (JVDJ)
Eur. J. Cancer 2020 Sep 01;137(xx)272-284, YJ Bang, T Golan, L Dahan, S Fu, V Moreno, K Park, R Geva, F De Braud, ZA Wainberg, M Reck, L Goff, N Laing, G Mi, JM Oliveira, H Wasserstrom, CC Lin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading